These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 26921201)

  • 1. Stochastic modelling of the eradication of the HIV-1 infection by stimulation of latently infected cells in patients under highly active anti-retroviral therapy.
    Sánchez-Taltavull D; Vieiro A; Alarcón T
    J Math Biol; 2016 Oct; 73(4):919-46. PubMed ID: 26921201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stochastic population switch may explain the latent reservoir stability and intermittent viral blips in HIV patients on suppressive therapy.
    Wang S; Rong L
    J Theor Biol; 2014 Nov; 360():137-148. PubMed ID: 25016044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART.
    Sedaghat AR; Siliciano RF; Wilke CO
    BMC Infect Dis; 2008 Jan; 8():2. PubMed ID: 18171475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Latently infected cell activation: a way to reduce the size of the HIV reservoir?
    Forde J; Volpe JM; Ciupe SM
    Bull Math Biol; 2012 Jul; 74(7):1651-72. PubMed ID: 22562387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
    Pierson T; McArthur J; Siliciano RF
    Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stochastic Dynamics of the Latently Infected Cell Reservoir During HIV Infection.
    Azoz SA; Coombs D
    Bull Math Biol; 2019 Jan; 81(1):131-154. PubMed ID: 30298198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV Replication and Latency in a Humanized NSG Mouse Model during Suppressive Oral Combinational Antiretroviral Therapy.
    Satheesan S; Li H; Burnett JC; Takahashi M; Li S; Wu SX; Synold TW; Rossi JJ; Zhou J
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29343582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asymmetric division of activated latently infected cells may explain the decay kinetics of the HIV-1 latent reservoir and intermittent viral blips.
    Rong L; Perelson AS
    Math Biosci; 2009 Jan; 217(1):77-87. PubMed ID: 18977369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of HIV latent infection model with multiple infection stages and different drug classes.
    Alshorman A; Al-Hosainat N; Jackson T
    J Biol Dyn; 2022 Dec; 16(1):713-732. PubMed ID: 36264087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 Reservoirs During Suppressive Therapy.
    Barton K; Winckelmann A; Palmer S
    Trends Microbiol; 2016 May; 24(5):345-355. PubMed ID: 26875617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children.
    Persaud D; Pierson T; Ruff C; Finzi D; Chadwick KR; Margolick JB; Ruff A; Hutton N; Ray S; Siliciano RF
    J Clin Invest; 2000 Apr; 105(7):995-1003. PubMed ID: 10749578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The amplitudes of viral blips in HIV-1 infected patients treated with antiretroviral therapy are power-law distributed.
    Percus JK; Percus OE; Di Mascio M
    J Theor Biol; 2009 Apr; 257(3):454-9. PubMed ID: 19171155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART.
    Sedaghat AR; Siliciano JD; Brennan TP; Wilke CO; Siliciano RF
    PLoS Pathog; 2007 Aug; 3(8):e122. PubMed ID: 17784786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral and latent reservoir persistence in HIV-1-infected patients on therapy.
    Kim H; Perelson AS
    PLoS Comput Biol; 2006 Oct; 2(10):e135. PubMed ID: 17040122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reservoirs of HIV-1 in vivo: implications for antiretroviral therapy.
    Saksena NK; Potter SJ
    AIDS Rev; 2003; 5(1):3-18. PubMed ID: 12875103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.
    Petravic J; Rasmussen TA; Lewin SR; Kent SJ; Davenport MP
    J Virol; 2017 May; 91(9):. PubMed ID: 28202759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamics of a new HIV model with the activation status of infected cells.
    Guo T; Qiu Z; Shen M; Rong L
    J Math Biol; 2021 Apr; 82(6):51. PubMed ID: 33860365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune activation despite suppressive highly active antiretroviral therapy is associated with higher risk of viral blips in HIV-1-infected individuals.
    Zoufaly A; Kiepe JG; Hertling S; Hüfner A; Degen O; Feldt T; Schmiedel S; Kurowski M; van Lunzen J
    HIV Med; 2014 Sep; 15(8):449-57. PubMed ID: 24580846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.